EGFR and non-small cell lung carcinoma: In a subgroup analysis of patients with EGFR mutation in a phase III trial (IMpower150) comparing CBDCA + PTX + bevacizumab + atezolizumab (ABCP) with CBDCA + PTX + bevacizumab (BCP) in the first-line treatment of non-squamous NSCLC, mOS was not reached vs. 18.7 months (HR 0.61, 95% CI: 0.29–1.28) and mPFS was 10.2 months vs. 6.9 months (HR 0.61, 95% CI: 0.36–1.28), showing a trend towards better treatment response in the atezolizumab combination group [60].